Development of a biochemical diagnosis of Parkinson disease by detection of α-synuclein misfolded aggregates in cerebrospinal fluid

JAMA Neurology

Volumn 74, Issue 2, 2017, Pages 163-172

  Shahnawaz, Mohammad ^a   Tokuda, Takahiko ^b,c   Waraga, Masaaki ^d   Mendez, Nicolas ^a   Ishii, Ryotaro ^b   Trenkwalder, Claudia ^e,f   Mollenhauer, Brit ^e,f   Soto, Claudio ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d Higashi Matsudo City Hospital   (Japan)

^e Paracelsus Elena Klinik Kassel   (Germany)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; OLIGOMER; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; TAU PROTEIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; BIOCHEMICAL ANALYSIS; BODY FLUID; CEREBROSPINAL FLUID; COHORT ANALYSIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; GERMANIC PEOPLE; HOEHN AND YAHR SCALE; HUMAN; IN VITRO STUDY; JAPANESE (PEOPLE); KINETICS; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PREDICTIVE VALUE; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN FOLDING; PROTEIN MISFOLDING CYCLIC AMPLIFICATION; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; SYNUCLEINOPATHY; BIOCHEMISTRY; CHEMISTRY; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC TEST; DIFFUSE LEWY BODY DISEASE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PROTEINOSIS; PROTEOSTASIS DEFICIENCY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SHY DRAGER SYNDROME;

ALPHA-SYNUCLEIN; AMYLOID BETA-PEPTIDES; BIOCHEMICAL PHENOMENA; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HUMANS; IN VITRO TECHNIQUES; LEWY BODY DISEASE; MALE; MULTIPLE SYSTEM ATROPHY; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEOSTASIS DEFICIENCIES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 85014678606     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.4547     Document Type: Article

References (57)

1. Jankovic J. Parkinson's disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376.
2. Baba M, Nakajo S, Tu PH, et al. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. AmJ Pathol. 1998;152(4):879-884.
3. Miraglia F, Betti L, Palego L, Giannaccini G. Parkinson's disease and alpha-synucleinopathies: From arising pathways to therapeutic challenge. Cent Nerv Syst Agents Med Chem. 2015;15(2):109-116.
4. Dickson DW. Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med. 2012;2(8):2.
5. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. α-Synuclein fibrillogenesis is nucleation-dependent: Implications for the pathogenesis of Parkinson's disease. J Biol Chem. 1999;274(28):19509-19512.
6. Bhak G, Lee JH, Hahn JS, Paik SR. Granular assembly of α-synuclein leading to the accelerated amyloid fibril formation with shear stress. PLoS One. 2009;4(1):e4177.
7. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55 (3):181-184.
8. Rajput AH, Rajput A. Accuracy of Parkinson disease diagnosis unchanged in 2 decades. Neurology. 2014;83(5):386-387.
9. Miller DB, O'Callaghan JP. Biomarkers of Parkinson's disease: Present and future. Metabolism. 2015;64(3)(suppl 1):S40-S46.
10. Roberts HL, Brown DR. Seeking a mechanism for the toxicity of oligomeric α-synuclein. Biomolecules. 2015;5(2):282-305.
11. Rockenstein E, Nuber S, Overk CR, et al. Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain. 2014;137(pt 5):1496-1513.
12. Kalia LV, Kalia SK, McLean PJ, Lozano AM, Lang AE. α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol. 2013;73(2):155-169.
13. Compta Y, Valente T, Saura J, et al. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease. J Neurol. 2015;262 (2):294-306.
14. Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010;75(20):1766-1772.
15. El-Agnaf OM, Salem SA, Paleologou KE, et al. Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006;20(3):419-425.
16. Hansson O, Hall S, Ohrfelt A, et al. Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimers Res Ther. 2014;6 (3):25.
17. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature. 2001; 411(6839):810-813.
18. Soto C, Saborio GP, Anderes L. Cyclic amplification of protein misfolding: Application to prion-related disorders and beyond. Trends Neurosci. 2002;25(8):390-394.
19. Saa P, Castilla J, Soto C. Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. J Biol Chem. 2006;281(46):35245-35252.
20. Castilla J, Saa P, Soto C. Detection of prions in blood. Nat Med. 2005;11(9):982-985.
21. Saa P, Castilla J, Soto C. Presymptomatic detection of prions in blood. Science. 2006;313 (5783):92-94.
22. Gonzalez-Romero D, Barria MA, Leon P, Morales R, Soto C. Detection of infectious prions in urine. FEBS Lett. 2008;582(21-22):3161-3166.
23. Moda F, Gambetti P, Notari S, et al. Prions in the urine of patients with variant Creutzfeldt-Jakob disease. N Engl J Med. 2014;371(6):530-539.
24. Concha-Marambio L, Pritzkow S, Moda F, et al. Highly sensitive and specific detection of prions in blood of variant Creutzfeldt-Jakob disease patients. Sci Transl Med. 2015;207:47-61.
25. Morales R, Duran-Aniotz C, Diaz-Espinoza R, Camacho MV, Soto C. Protein misfolding cyclic amplification of infectious prions. Nat Protoc. 2012; 7(7):1397-1409.
26. Saa P, Cervenakova L. Protein misfolding cyclic amplification (PMCA): Current status and future directions. Virus Res. 2014.
27. Salvadores N, ShahnawazM, Scarpini E, Tagliavini F, Soto C. Detection of misfolded Aβ oligomers for sensitive biochemical diagnosis of Alzheimer's disease. Cell Rep. 2014;7(1):261-268.
28. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: A cohort study. Lancet Neurol. 2011; 10(3):230-240.
29. Mollenhauer B, Trautmann E, Sixel-Doring F, et al.; DeNoPa Study Group. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology. 2013;81(14):1226-1234.
30. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology. 1967;17(5): 427-442.
31. Goetz CG, PoeweW, Rascol O, et al.; Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations. Mov Disord. 2004;19(9):1020-1028.
32. Mollenhauer B, Trautmann E, Taylor P, et al. Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci Lett. 2013;532:44-48.
33. Roostaee A, Beaudoin S, Staskevicius A, Roucou X. Aggregation and neurotoxicity of recombinant α-synuclein aggregates initiated by dimerization. Mol Neurodegener. 2013;8:5.
34. Meyer V, Dinkel PD, Rickman Hager E, Margittai M. Amplification of Tau fibrils from minute quantities of seeds. Biochemistry. 2014;53(36): 5804-5809.
35. LeVine H III. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci. 1993;2(3):404-410.
36. Jellinger KA. Lewy body-related α-synucleinopathy in the aged human brain. J Neural Transm (Vienna). 2004;111(10-11):1219-1235.
37. Walker L, McAleese KE, Thomas AJ, et al. Neuropathologically mixed Alzheimer's and Lewy body disease: Burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol. 2015;129(5):729-748.
38. Hamilton RL. Lewy bodies in Alzheimer's disease: A neuropathological review of 145 cases using α-synuclein immunohistochemistry. Brain Pathol. 2000;10(3):378-384.
39. Lleo A, Cavedo E, Parnetti L, et al. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol. 2015;11(1):41-55.
40. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003;4(1):49-60.
41. Atarashi R, Wilham JM, Christensen L, et al. Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking. Nat Methods. 2008;5(3):211-212.
42. Mays CE, Ryou C. Plasminogen stimulates propagation of protease-resistant prion protein in vitro. FASEB J. 2010;24(12):5102-5112.
43. Murayama Y, YoshiokaM, Masujin K, et al. Sulfated dextrans enhance in vitro amplification of bovine spongiform encephalopathy PrP(Sc) and enable ultrasensitive detection of bovine PrP(Sc). PLoS One. 2010;5(10):5.
44. Rubenstein R, Chang B, Gray P, et al. A novel method for preclinical detection of PrPSc in blood. J Gen Virol. 2010;91(pt 7):1883-1892.
45. Thorne L, Terry LA. In vitro amplification of PrPSc derived from the brain and blood of sheep infected with scrapie. J Gen Virol. 2008;89(pt 12): 3177-3184.
46. Haley NJ, Seelig DM, Zabel MD, Telling GC, Hoover EA. Detection of CWD prions in urine and saliva of deer by transgenic mouse bioassay. PLoS One. 2009;4(3):e4848.
47. Murayama Y, Masujin K, ImamuraM, et al. Ultrasensitive detection of PrP(Sc) in the cerebrospinal fluid and blood of macaques infected with bovine spongiform encephalopathy prion. J Gen Virol. 2014;95(pt 11):2576-2588.
48. Lacroux C, Comoy E, Moudjou M, et al. Preclinical detection of variant CJD and BSE prions in blood. PLoS Pathog. 2014;10(6):e1004202.
49. McDowell KL, Nag N, Franco Z, et al. Blood reference materials from macaques infected with variant Creutzfeldt-Jakob disease agent. Transfusion. 2015;55(2):405-412.
50. Atarashi R, Satoh K, Sano K, et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med. 2011;17(2):175-178.
51. Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study. Neurology. 2014; 83(5):406-412.
52. Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R. Interaction between Aβ peptide and alpha synuclein: Molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res. 2006;31(9):1153-1162.
53. Tsigelny IF, Crews L, Desplats P, et al. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One. 2008;3(9):e3135.
54. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between Aβ, tau, and α-synuclein: Acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30(21):7281-7289.
55. Ono K, Takahashi R, Ikeda T, Yamada M. Cross-seeding effects of amyloid β-protein and α-synuclein. J Neurochem. 2012;122(5):883-890.
56. Morales R, Moreno-Gonzalez I, Soto C. Cross-seeding of misfolded proteins: Implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathog. 2013;9(9):e1003537.
57. Lee VM, Giasson BI, Trojanowski JQ. More than just two peas in a pod: Common amyloidogenic properties of tau and α-synuclein in neurodegenerative diseases. Trends Neurosci. 2004;27(3):129-134.